Adial Pharmaceuticals, Inc

Contributing Author

Recent Articles by Adial Pharmaceuticals, Inc

4 hours	Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update ADIL GlobeNewswire
Apr-29	Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 ADIL GlobeNewswire
Apr-27	Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program ADIL GlobeNewswire
Apr-22	Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial ADIL GlobeNewswire
Mar-24	Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans ADIL -8.15% GlobeNewswire
Mar-06	Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update ADIL -7.11% GlobeNewswire
Mar-03	Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement ADIL -7.29% GlobeNewswire
Feb-24	Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement ADIL GlobeNewswire
Feb-23	Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One ADIL GlobeNewswire
Feb-17	Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference ADIL -5.26% GlobeNewswire
Feb-04	Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 ADIL -25.79% GlobeNewswire
Feb-03	Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement ADIL GlobeNewswire
Jan-14	Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 ADIL GlobeNewswire
Nov-26	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds ADIL GlobeNewswire
Nov-14	Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update ADIL GlobeNewswire
Oct-17	Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show ADIL GlobeNewswire
Oct-09	Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution ADIL GlobeNewswire
Sep-16	Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 ADIL GlobeNewswire
Sep-03	Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule ADIL GlobeNewswire
Aug-20	Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments ADIL GlobeNewswire
Aug-14	Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update ADIL GlobeNewswire
Aug-06	Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting ADIL GlobeNewswire
Jul-16	Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement ADIL +10.05% GlobeNewswire
Jul-09	Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 ADIL GlobeNewswire
Jun-25	Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply ADIL +7.28% GlobeNewswire
Jun-17	Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering ADIL -25.99% GlobeNewswire
Jun-16	Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting ADIL -7.14% GlobeNewswire
Jun-11	Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 ADIL -23.77% GlobeNewswire
May-15	Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update ADIL GlobeNewswire
May-13	Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study ADIL GlobeNewswire
May-08	Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration ADIL GlobeNewswire
May-02	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds ADIL -14.10% GlobeNewswire
May-01	Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders ADIL +13.04% GlobeNewswire

Adial Pharmaceuticals, Inc

Recent Articles by Adial Pharmaceuticals, Inc

Upgrade your Finviz experience